NutraLife Accelerates Expansion Into the Rapidly Growing $11 Billion CBD Industry

NutraLife Biosciences

KOR Medical CBD-infused wellness products
KOR Medical CBD-infused wellness products
KOR Medical CBD-infused wellness products

COCONUT CREEK, FL, Jan. 10, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – NutraLife Biosciences Inc. (OTC: NLBS) announces a feature article released by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, covering NutraLife’s rapidly growing expansion plans.

CBD has become one of the fastest-growing wellness products globally, reaching more than $11 billion in global sales last year. According to Market Data Forecast, these sales will continue to grow at a 22.2% annual pace to nearly $31 billion by 2026. As a result, companies building an early presence in the industry could be in a great position to profit.

NutraLife Biosciences Inc. (OTC Pink: NLBS) began expanding into hemp-derived CBD in 2018. Since then, the company has built up a vertically-integrated presence in the CBD industry with experience growing in Wisconsin, partnerships with geneticists and master growers of high-quality indoor organic hemp flower, cGMP manufacturing facilities in Florida, and a growing list of in-house and private-label CBD brands.

In this article, we’ll look at the company’s CBD footprint and its recent progress to expand into the rapidly growing industry.

Vertically-Integrated Manufacturer

NutraLife Biosciences subsidiary, PhytoChem Technologies, and its partners, cultivate, harvest, process, and distribute high-quality hemp flower. The company’s cultivation partners are based in Wisconsin, where they have hemp licenses from the Department of Agriculture.

Currently, the company offers 13 different core formulations and 50 variations of those formulations for private label customers, including CBD-infused oral sprays, tinctures, pet drops, pain balms, and face creams. The company also offers a range of non-CBD products, including anti-bacterial sprays and gels, immune supplements, and bug patches.

From Private-Label to Brands

NutraLife Biosciences recently partnered with KOR Medical to develop a line of CBD-infused wellness products. In December, the company completed an initial order for four ingestible products, including KOR Calm, KOR Health, KOR Relief, and KOR Sleep, which are already for sale to consumers on KOR’s online platform.

NutraLife’s private label items are already for sale on KORMedical.com. Source: KOR Medical

Through these kinds of agreements, the company could generate recurring revenue from repeat contract manufacturing. The company is also leveraging its experience launching and distributing products to expand its own product lines, including a cannabinoid-infused beauty and wellness product line.

Finally, the company’s scientists are constantly pushing the envelope when it comes to innovative delivery systems. For instance, its INVISIPATCH is a bug patch technology designed to deter mosquitoes and other biting insects. The company also developed an antiseptic spray for export to Indonesia to minimize viral loads in the mouth.

Looking Ahead

NutraLife Biosciences Inc. (OTC Pink: NLBS) has spent the past couple of years building a compelling presence in the CBD business with multi-state resources including Wisconsin and manufacturing facilities in Florida. In addition to building out its CBD business, the company continues to push the envelope with new products in diverse sectors.

For more information, visit https://nutralifebiosciences.com/

Forward-Looking Statements

This press release contains statements of a forward-looking nature about NutraLife Biosciences, Inc. (the “Company”). You can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements primarily on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on the Company’s information on the date hereof. These statements involve known and unknown risks, uncertainties, and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors is set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on June 24, 2021. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

Contact:
NutraLife BioSciences, Inc.
6601 Lyons Road, Suite L-6
Coconut Creek, FL 33073
Telephone 888-509-8901
www.NutraLifeBioSciences.com

Attachment

NutraLife Biosciences Partners with KOR Medical to Create Cannabinoid-Based Wellness Products

COCONUT CREEK, FL, Dec. 17, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — NutraLife Biosciences Inc. (OTC: NLBS) announces a strategic partnership with KOR Medical and completes an initial order for a line of cannabinoid-based wellness products.

The initial products produced under this venture is a line of four ingestible items formulated to help improve overall health, including helping consumers sleep better, feel better, be calmer, and improve their quality of life.

Cannabinoids are natural compounds found in the cannabis plant. Dozens have been discovered, and many are known to cause different effects in the human body. One of the more well-known cannabinoids is CBD, which is said to decrease pain, reduce inflammation, and decrease anxiety. CBD is commonly extracted from industrial hemp and processed into oil and other products.

NutraLife Biosciences Inc., based in Coconut Creek, Fla., is a recognized manufacturer and distributor of private label and branded nutraceutical and skincare products. Over the last eight years, the company has created more than 50 products. It also has developed different ways to ingest them efficiently, including sprays, tinctures, and oral strips.

KOR Medical, based in Charleston, S.C., is a health and wellness company that performs extensive research and development into cannabinoids to find the most effective combinations for different people and different health conditions. With a goal of being “focused on alternative solutions for better futures,” the company also provides education to consumers about how various cannabinoids interact with the body.

Edgar Ward, NutraLife Biosciences President/CEO, said the partnership will benefit both companies as well as consumers seeking effective health and wellness solutions.

“We are both honored and grateful to be working with an exceptional like-minded organization focused on providing innovation in the medical cannabis industry,” Ward said. “We’ve enjoyed working with KOR Medical to provide these unique personalized cannabinoid formulations that support and help improve quality of life.”

Scotty Branch Co-Founder added:

“This collaboration with NutraLife Sciences can be deemed as progress towards innovative solutions powered by the plant. Our mission at KOR is to formulate, innovate and research cannabinoid products that have a therapeutic value to the consumer on a personal level. This partnership will accelerate our ability to make an impact in these areas. We look forward to the future and unveiling to the world the special attributes of the plant which will make an impact on society for years to come.”

Lindsey Leech, DNP, NP-C

Executive VP of Medical Affairs

Vikor Scientific, Charleston, S.C.

“At KOR Medical, we have a diverse leadership team of medical professionals, cannabis experts, and successful entrepreneurs who have all seen the benefits of cannabinoids first-hand. Collaborating with NutraLife Biosciences has helped us bring life-changing, wellness alternatives to fruition that will exceed mainstream methods for many years to come.”

“The new products produced by NutraLife Biosciences will be delivered and sold through KOR’s platform. The initial line includes KOR Calm, KOR Health, KOR Relief and KOR Sleep.”

For more information about NutraLife Bioscience visit NutraLifeBioSciences.com

For more information about KOR Medical visit kormedical.com

Forward-Looking Statements

This press release contains statements of a forward-looking nature about NutraLife Biosciences, Inc. (the “Company”). You can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements primarily on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on the Company’s information on the date hereof. These statements involve known and unknown risks, uncertainties, and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors is set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on June 24, 2021, as amended. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

Contact:

NutraLife BioSciences, Inc.

6601 Lyons Road, Suite L-6

Coconut Creek, FL 33073

Telephone 888-509-8901

www.NutraLifeBioSciences.com

NutraLife Biosciences Inc. (NLBS) Announces the Company’s Financial Fully Reporting Status

Coconut Creek, FL, Aug. 05, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — NutraLife Biosciences, Inc. (“NutraLife” or the “Company”) (OTC: NLBS) is pleased to announce that it has obtained current, fully reporting status through the filing of the Company’s financial statements. Please see the following link below to the Company’s financial statements filed with the Securities and Exchange Commission. NutraLife is excited about the potential this step creates for future growth of the Company.

The Company’s continued focus is on increasing its revenue, a goal it intends to achieve through the distribution and sale of the Company’s lifestyle health and wellness, nutraceutical, and skincare branded product lines. As a lifestyle health and wellness manufacturing firm, NutraLife is dedicated to creating growth through the high-quality, effective, beneficial nutrients that it brings to market to improve lives.

Like many other lifestyle health and wellness manufacturing firms, NutraLife has faced a wide range of challenges over the past few years due to changing industry regulations and the global COVID-19 pandemic. However, the Company has made headway on several business development fronts that show great promise to increase cash flows through multiple streams.

With this achievement, the Company expects that it will see an improvement in the Company’s fundamentals through aggressive distribution and sales initiatives of a multitude of products. Given the increasing demand for lifestyle health and wellness products that deliver solid nutritional results, the manufacturing firm also sees the opportunity for strong growth long into the future.

The sales initiatives that have been planned for the lifestyle health and wellness manufacturing firm are expected to include web and retail sales of daily health and wellness nutraceutical and skincare products that are produced and distributed by NutraLife Biosciences.

The Company is optimistic in its projected outcome from the initiatives. Based on current industry sales and distribution data, the initiatives include multiple strategic partnerships NutraLife has formed to facilitate the Company’s plan and drive sales revenue to ensure growth for the lifestyle health and wellness manufacturing firm.

“Although over the last few years we have had many unexpected hurdles to overcome, we have done just that and overcome them, and we plan to continue to overcome any challenges that come our way. We are confident in our capabilities, and our partners, and look forward to the days ahead as we continue to build value for the Company and its shareholders. I would like to take this opportunity to thank our shareholders for their support over the years, and we are grateful to those whose contributions have helped us in our time of need. Thank you all, and we look forward to being of value,” said Edgar Ward, NutraLife Biosciences President/CEO.

About the Company
NutraLife Biosciences, Inc. operates a multifaceted life sciences and lifestyle health and wellness manufacturing company. For more than eight years, NutraLife has manufactured and distributed both private label and branded nutraceutical and skincare wellness products.

Link to financial statements: https://www.sec.gov/edgar/browse/?CIK=1563463&owner=exclude

Forward-Looking Statements
This press release contains statements of a forward-looking nature about NutraLife Biosciences, Inc. (the “Company”). You can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements primarily on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on the Company’s information on the date hereof. These statements involve known and unknown risks, uncertainties, and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors is set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on June 24, 2021. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

Contact:
NutraLife Biosciences, Inc.
6601 Lyons Road, Suite L-6
Coconut Creek, FL 33073
Telephone 888-509-8901
www.NutraLifeBioSciences.com

NutraLife Biosciences Inc. (NLBS) Obtains Current Fully Reporting Status

Coconut Creek, FL, July 20, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — NutraLife Biosciences, Inc. (“NutraLife” or the “Company”) (OTC: NLBS) is pleased to announce that it has obtained current, fully reporting status through the filing of the Company’s financial statements. Please see the following link below to the Company’s financial statements filed with the Securities and Exchange Commission. NutraLife is excited about the potential this step creates for future growth of the Company.

The Company’s continued focus is on increasing its revenue, a goal it intends to achieve through the distribution and sale of the Company’s lifestyle health and wellness, nutraceutical, and skincare branded product lines. As a lifestyle health and wellness manufacturing firm, NutraLife is dedicated to creating growth through the high-quality, effective, beneficial nutrients that it brings to market to improve lives.

Like many other lifestyle health and wellness manufacturing firms, NutraLife has faced a wide range of challenges over the past few years due to changing industry regulations and the global COVID-19 pandemic. However, the Company has made headway on several business development fronts that show great promise to increase cash flows through multiple streams.

With this achievement, the Company expects that it will see an improvement in the Company’s fundamentals through aggressive distribution and sales initiatives of a multitude of products. Given the increasing demand for lifestyle health and wellness products that deliver solid nutritional results, the manufacturing firm also sees the opportunity for strong growth long into the future.

The sales initiatives that have been planned for the lifestyle health and wellness manufacturing firm are expected to include web and retail sales of daily health and wellness nutraceutical and skincare products that are produced and distributed by NutraLife Biosciences.

The Company is optimistic in its projected outcome from the initiatives. Based on current industry sales and distribution data, the initiatives include multiple strategic partnerships NutraLife has formed to facilitate the Company’s plan and drive sales revenue to ensure growth for the lifestyle health and wellness manufacturing firm.

“Although over the last few years we have had many unexpected hurdles to overcome, we have done just that and overcome them, and we plan to continue to overcome any challenges that come our way. We are confident in our capabilities, and our partners, and look forward to the days ahead as we continue to build value for the Company and its shareholders. I would like to take this opportunity to thank our shareholders for their support over the years, and we are grateful to those whose contributions have helped us in our time of need. Thank you all, and we look forward to being of value,” said Edgar Ward, NutraLife Biosciences President/CEO

About the Company

NutraLife Biosciences, Inc. operates a multifaceted life sciences and lifestyle health and wellness manufacturing company. For more than eight years, NutraLife has manufactured and distributed both private label and branded nutraceutical and skincare wellness products.

Link to financial statements: https://www.sec.gov/edgar/browse/?CIK=1563463&owner=exclude

Forward-Looking Statements

This press release contains statements of a forward-looking nature about NutraLife Biosciences, Inc. (the “Company”). You can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements primarily on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on the Company’s information on the date hereof. These statements involve known and unknown risks, uncertainties, and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors is set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on June 24, 2021. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

Contact:

NutraLife Biosciences, Inc.

6601 Lyons Road, Suite L-6

Coconut Creek, FL 33073

Telephone 888-509-8901

www.NutraLifeBioSciences.com

NutraLife BioSciences, Inc. Receives Reorder and Begins Production of The Oral Sanitizer Mouth Spray For Indonesian Distributor Kinerjapay Corp.

Coconut Creek, FL, Feb. 11, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — NutraLife BioSciences, Inc. (“NutraLife” or the “Company”) (OTC: NLBS) today announced that it received a reorder and has now begun production of 87,500 units for 27 Health’s Oral Sanitizer mouth spray being produced by NLBS. This is the second order after the initial order of 25,000 units that were manufactured, exported, and delivered to Kinerjapay Corp. (OTC: KPAY) for distribution throughout Indonesia back in late January.

The Company and its partners have begun distributing the product providing a convenient, travel-size, multi-functioning antiseptic, breath-freshening mouth spray for consumers to use throughout the day. We believe that mouthwash products can be effective at killing viruses, reducing the viral load within the mouth essentially supporting the reduction of virus transmissions.

The feedback from KPAY is that the product is being well received and they anticipate increased demand as they roll-out the product with plans to expand their distribution reach into other countries.

“The launch of the international version of 27 Health’s Oral Shield mouth spray product has been very successful,” said Joseph Frontiere, CEO of 27 Health. Kinerjapay Corp. CEO Edwin Ng stated, “We are receiving an excellent response to our initial marketing of the Oral Sanitizer, the international version of Oral Shield. We anticipate selling over 1 million bottles this year mainly in Indonesia. However, demand could be much greater.”

NLBS plans to continue on its path providing various health and wellness products while adapting to the ever-changing environment. The company is also in the process of finalizing the Company’s financials to bring the Company current while continuing to drive sales revenue. Over the years, the Company has developed and acquired many products, including the Company’s patented derma-bug-patch insect repellent, a line of CBD products, and now a line of sanitizer products, with several other health and wellness products in development that the Company will manufacture and distribute in the very near future.

About the Company

NutraLife BioSciences, Inc. operates a multifaceted life sciences company. For more than seven years, NutraLife has manufactured and distributed private label and branded nutraceutical and skincare wellness products.

Forward-Looking Statements

This press release contains statements of a forward-looking nature about NutraLife Biosciences, Inc. (the “Company”). You can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements primarily on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on the Company’s information on the date hereof. These statements involve known and unknown risks, uncertainties, and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors is set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission on April 2, 2019, as amended. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

Contact:

NutraLife BioSciences, Inc.

6601 Lyons Road, Suite L-6

Coconut Creek, FL 33073

Telephone 888-509-8901

www.NutraLifeBioSciences.com

Industrial Hemp Plants on NutraLife’s Contracted 10 Acre Field in Wisconsin Growing Fast

Coconut Creek, Florida, July 30, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NutraLife Biosciences, Inc. (OTCQB: NLBS) (the “Company” or “NutraLife”) provides another promising update on the industrial hemp crop being grown and operated by Mike Hoyer and Zachary Trimble, operations manager of NutraLife’s subsidiary, PhytoChem Technologies, Inc. (“PhytoChem”).

Mr. Trimble says that “hemp plants are growing faster than ever,” according to his daily log on July 12, adding on the 26th that “this week has been all about weed management” and that “plants are still growing and look healthy overall.”

Pursuant to a Crop Operations Agreement with NutraLife’s wholly owned subsidiary, PhytoChem, the Company purchased and Hoyer planted approximately 20,000 industrial hemp seedlings in June. PhytoChem plans to commercialize the Crop using its two licenses from the Wisconsin Department of Agriculture to grow and process industrial hemp within the state.

“Mike and Zachary are doing an amazing job,” says NutraLife’s Chief Executive Officer and President, Edgar Ward. “Their work not only ensures a rich harvest with this Crop, but also generates valuable data and insight to expand our crops and footprint in 2020.”

Driven by its mission to bringing high quality, effective and beneficial nutrients to market, NutraLife continues to strengthen its vertical positioning within the hemp industry. NutraLife’s operations include industrial hemp cultivation and processingproduct research and development, retail sale of its own branded products and affiliate and private label wholesale.

Underpinning this strategy, NutraLife’s new commercial extraction equipment known as the Ennea Processor is presently being manufactured and will be used to process the industrial hemp crop grown in Wisconsin. The Ennea Processor targets and extracts bioactive compounds from whole-plant hemp crops and streamlines production times and maximizes extraction yields.

“The cultivation is progressing very well and we expect the processing systems to be operating at our facilities no later than October of this year. We expect to be very well positioned to distribute high quality phytocannabinoid rich products to our customers and our private label partners,” explains Ward.

About NutraLife BioSciences

Edgar Ward founded NutraLife in 2010 as NutraFuels, Inc. and since that time he has served as its Chief Executive Officer, President, and Director. Under Mr. Ward’s direction, NutraLife’s revenues increased from $225,000 in 2016 to more than $3.7 million in 2018. NutraLife’s Coconut Creek manufacturing facility has been registered with the Food and Drug Administration, and its manufacturing facility has operated in accordance with the Good Manufacturing Processes Standard (GMP) for more than five years. NutraLife’s products are tested by its in-house laboratory chemists for strength, purity and contaminants such as heavy metals, pesticides, and solvents. NutraLife offers seventeen different core formulations, which it modifies to meet the specifications of its private label customers. NutraLife provides approximately 50 different variations of its core formulations. NutraLife’s private label products include CBD infused oral sprays, tinctures, pet drops, pain balms, face creams, and nutraceutical oral spray products that support daily health and wellness uses.

Forward-Looking Statements

This press release contains statements of a forward-looking nature about NutraLife BioSciences, Inc. (“NutraLife” or the “Company”). These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect the Company’s financial condition, results of operations, business strategy and financial needs. There is no assurance that the Company’s current expectations and projections are accurate or that the Company’s plans to process hemp with GEG will be successful. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on April 2, 2019. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on the Company’s business or the extent to which any factor or combination of factors may cause actual results to differ from those contained in any forward-looking statements. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under SEC guidelines.

Company Contact:

NutraLife BioSciences, Inc.

6601 Lyons Road, Suite L-6

Coconut Creek, FL 33073

Telephone 888-509-8901

www.NutraLifeBioSciences.com

NutraLife Biosciences, Inc. Announces Update on Contracted 10 Acre Industrial Hemp Grow in Wisconsin with Joint Venture Farming Partner

Coconut Creek, Florida, June 27, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NutraLife Biosciences, Inc. (OTCQB: NLBS) (the “Company” or “NutraLife”) provides a promising update on the industrial hemp crop being grown and operated by Mike Hoyer and PhytoChem employee Zachary Trimble pursuant to a Crop Operations Agreement with NutraLife’s wholly owned subsidiary, PhytoChem Technologies, Inc. (“PhytoChem”). Under the terms of the Crop Operations Agreement, NutraLife delivered approximately 20,000 industrial hemp seedlings to Hoyer earlier this month which PhytoChem plans to commercialize. The plants on the budding field are in excellent condition: “They look strong and healthy,” according to Trimble’s daily log on June 19, adding “even the few plants that didn’t seem like they were going to make it show signs of life.”

Earlier this year, NutraLife received two licenses from the Wisconsin Department of Agriculture to grow and process industrial hemp within the state. Wisconsin, according to a recent Hemp Industry Daily report, was deemed a ‘new and emerging market’ for hemp and hemp production. The report also names Wisconsin the ‘fastest-moving state yet to allow hemp industry to take root.’ 
[>>> Link to https://bit.ly/2XX5zlA]

After the licenses were issued, NutraLife, through its subsidiary PhytoChem, also entered into an agreement with Henning Trading LLC (“Henning Trading”), to consult and advise on the cultivation and harvest of the hemp grow in Wisconsin. Henning Trading is well known for its expertise in the agriculture industry. Besides, NutraLife and Henning Trading plan to explore participation in the hemp seed propagation, fiber and grain markets. 
[>>> Link to https://bit.ly/2L1z9CV]

Last week the Company announced that its subsidiary PhytoChem placed the first order under its exclusive agreement with Owen J. Morgan for a commercial machine – the Ennea Processor – which will be used to process the industrial hemp grown in Wisconsin. The Ennea Processor targets and extracts bioactive compounds from whole plant hemp crops and streamlines production times and maximizes extraction yields. 
[>>> Link to https://bit.ly/2ZxOqPR]

NutraLife plans to continue to pursue vertical positioning within the hemp industry. “We look forward to continued growth and new opportunities in the Nutraceutical, Hemp and Life Sciences markets as we end the second quarter of 2019,” says NutraLife’s Chief Executive Officer and President, Edgar Ward. “We are very pleased with the promising developments in Wisconsin and look forward to a significant increase in revenue and working with our partners to advance the Company’s vertical positioning within the hemp industry,” he adds.

About NutraLife BioSciences

Edgar Ward founded NutraLife in 2010 as NutraFuels, Inc. and since that time he has served as its Chief Executive Officer, President, and Director. Under Mr. Ward’s direction, NutraLife’s revenues increased from $225,000 in 2016 to more than $3.7 million in 2018. NutraLife’s Coconut Creek manufacturing facility has been registered with the Food and Drug Administration, and its manufacturing facility has operated in accordance with the Good Manufacturing Processes Standard (GMP) for more than five years. NutraLife’s products are tested by its in-house laboratory chemists for strength, purity and contaminants such as heavy metals, pesticides, and solvents. NutraLife offers seventeen different core formulations which it modifies to meet the specifications of its private label customers. NutraLife provides approximately 50 different variations of its core formulations. NutraLife’s private label products include CBD infused oral sprays, tinctures, pet drops, pain balms, face creams, and nutraceutical oral spray products that support daily health and wellness uses.

Forward-Looking Statements

This press release contains statements of a forward-looking nature about NutraLife BioSciences, Inc. (“NutraLife” or the “Company”). These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect the Company’s financial condition, results of operations, business strategy and financial needs. There is no assurance that the Company’s current expectations and projections are accurate or that the Company’s plans to process hemp with GEG will be successful. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the Section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on April 2, 2019. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on the Company’s business or the extent to which any factor or combination of factors may cause actual results to differ from those contained in any forward-looking statements. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under SEC guidelines.

Company Contact:

NutraLife BioSciences, Inc.
6601 Lyons Road, Suite L-6
Coconut Creek, FL 33073
Telephone 888-509-8901
www.NutraLifeBioSciences.com

DGAP-News: NutraLife BioSciences, Inc. Orders Its First Ennea Processor Under Its Exclusive Agreement with Owen J. Morgan for Use in Wisconsin

DGAP-News: NutraLife Biosciences, Inc. / Key word(s): Miscellaneous
NutraLife BioSciences, Inc. Orders Its First Ennea Processor Under Its Exclusive Agreement with Owen J. Morgan for Use in Wisconsin 

17.06.2019 / 09:29 
The issuer is solely responsible for the content of this announcement.


NutraLife BioSciences, Inc. Orders Its First Ennea Processor Under Its Exclusive Agreement with Owen J. Morgan for Use in Wisconsin

NutraLife BioSciences, Inc. Orders Its First Ennea Processor Under Its Exclusive Agreement with Owen J. Morgan for Use in Wisconsin

Coconut Creek, FL — NutraLife Biosciences, Inc. (OTCQB: NLBS) (the “Company” or “NutraLife”) announces that its subsidiary, PhytoChem Technologies, Inc. (“PhytoChem”), has placed the first order under its exclusive agreement with Owen J. Morgan for a commercial machine which it intends to use to process industrial hemp grown in Wisconsin. On March 14, 2019, NutraLife announced it had received two licenses from the Wisconsin Department of Agriculture to grow and process industrial hemp within the state.

The Ennea Processor targets and extracts bioactive compounds from whole plant hemp crops and streamlines production times and maximizes extraction yields while retaining the cellular and fiber integrity of the plants for further applications. Ennea’s system of pure oils recovery eliminates the need for secondary recovery methods.

“The Ennea Processor will process NutraLife’s industrial hemp biomass, and we will offer tolling services to other licensed growers,” says NutraLife’s Chief Executive Officer and President, Edgar Ward.

The order follows the successful demonstration and trial of the first working prototype of the Ennea Processor at NutraLife’s facilities earlier this month. The new results confirm full spectrum extraction of all bioactive compounds, including all terpenes. On the certified industrial hemp crop trials, Ennea extracted on average over 30% higher yields than was previously thought existing in the cannabinoid group.

“Quantitative lab results, following over 20 days of live trials with the Ennea prototype at NutraLife’s facilities, demonstrate the true ability of the Ennea Processor. We believe that Ennea will change bioactive compound extraction. I am excited to be working with NutraLife to develop the industrial hemp extractive market in North America,” said Owen J. Morgan.

The PhytoChem Ennea Processing Plant in Wisconsin is the first of NutraLife’s contracted growers for the 2019 growing season.

About NutraLife BioSciences

Edgar Ward founded NutraLife in 2010 as NutraFuels, Inc. and since that time he has served as its Chief Executive Officer, President and Director. Under Mr. Ward’s direction, NutraLife’s revenues increased from $225,000 in 2016 to more than $3.7 million in 2018. NutraLife’s Coconut Creek manufacturing facility has been registered with the Food and Drug Administration, and its manufacturing facility has operated in accordance with the Good Manufacturing Processes Standard (GMP) for more than five years. NutraLife’s products are tested by its in-house laboratory chemists for strength, purity and contaminants such as heavy metals, pesticides, and solvents. NutraLife offers thirteen different core formulations which it modifies to meet the specifications of its private label customers. NutraLife provides approximately 50 different variations of its core formulations. NutraLife’s private label products include CBD infused oral sprays, tinctures, pet drops, pain balms, face creams, and nutraceutical oral spray products that support daily health and wellness uses.

Forward-Looking Statements

This press release contains statements of a forward-looking nature about NutraLife BioSciences, Inc. (“NutraLife” or the “Company”). These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect the Company’s financial condition, results of operations, business strategy and financial needs. There is no assurance that the Company’s current expectations and projections are accurate or that the Company’s plans to process hemp with GEG will be successful. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the Section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on April 2, 2019. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on the Company’s business or the extent to which any factor or combination of factors may cause actual results to differ from those contained in any forward-looking statements. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under SEC guidlines.

Company Contact:

NutraLife BioSciences, Inc.
6601 Lyons Road, Suite L-6
Coconut Creek, FL 33073
Telephone 888-509-8901
www.NutraLifeBioSciences.com

NutraLife BioSciences, Inc. Orders Its First Ennea Processor Under Its Exclusive Agreement with Owen J. Morgan for Use in Wisconsin

Coconut Creek, FL, June 14, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NutraLife Biosciences, Inc. (OTCQB: NLBS) (the “Company” or “NutraLife”) announces that its subsidiary, PhytoChem Technologies, Inc. (“PhytoChem”), has placed the first order under its exclusive agreement with Owen J. Morgan for a commercial machine which it intends to use to process industrial hemp grown in Wisconsin.  On March 14, 2019, NutraLife announced it had received two licenses from the Wisconsin Department of Agriculture to grow and process industrial hemp within the state.

The Ennea Processor targets and extracts bioactive compounds from whole plant hemp crops and streamlines production times and maximizes extraction yields while retaining the cellular and fiber integrity of the plants for further applications. Ennea’s system of pure oils recovery eliminates the need for secondary recovery methods. 

“The Ennea Processor will process NutraLife’s industrial hemp biomass, and we will offer tolling services to other licensed growers,” says NutraLife’s Chief Executive Officer and President, Edgar Ward.

The order follows the successful demonstration and trial of the first working prototype of the Ennea Processor at NutraLife’s facilities earlier this month. The new results confirm full spectrum extraction of all bioactive compounds, including all terpenes. On the certified industrial hemp crop trials, Ennea extracted on average over 30% higher yields than was previously thought existing in the cannabinoid group.

“Quantitative lab results, following over 20 days of live trials with the Ennea prototype at NutraLife’s facilities, demonstrate the true ability of the Ennea Processor. We believe that Ennea will change bioactive compound extraction. I am excited to be working with NutraLife to develop the industrial hemp extractive market in North America,” said Owen J. Morgan.

The PhytoChem Ennea Processing Plant in Wisconsin is the first of NutraLife’s contracted growers for the 2019 growing season. 

About NutraLife BioSciences

Edgar Ward founded NutraLife in 2010 as NutraFuels, Inc. and since that time he has served as its Chief Executive Officer, President and Director. Under Mr. Ward’s direction, NutraLife’s revenues increased from $225,000 in 2016 to more than $3.7 million in 2018. NutraLife’s Coconut Creek manufacturing facility has been registered with the Food and Drug Administration, and its manufacturing facility has operated in accordance with the Good Manufacturing Processes Standard (GMP) for more than five years. NutraLife’s products are tested by its in-house laboratory chemists for strength, purity and contaminants such as heavy metals, pesticides, and solvents. NutraLife offers thirteen different core formulations which it modifies to meet the specifications of its private label customers. NutraLife provides approximately 50 different variations of its core formulations. NutraLife’s private label products include CBD infused oral sprays, tinctures, pet drops, pain balms, face creams, and nutraceutical oral spray products that support daily health and wellness uses.

Forward-Looking Statements

This press release contains statements of a forward-looking nature about NutraLife BioSciences, Inc. (“NutraLife” or the “Company”). These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect the Company’s financial condition, results of operations, business strategy and financial needs. There is no assurance that the Company’s current expectations and projections are accurate or that the Company’s plans to process hemp with GEG will be successful. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the Section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on April 2, 2019. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on the Company’s business or the extent to which any factor or combination of factors may cause actual results to differ from those contained in any forward-looking statements. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under SEC guidlines.

Company Contact:

NutraLife BioSciences, Inc.
6601 Lyons Road, Suite L-6
Coconut Creek, FL 33073
Telephone 888-509-8901
www.NutraLifeBioSciences.com

NutraLife Biosciences, Inc. (NLBS) Reports First Quarter 2019 Results

Coconut Creek, FL, May 17, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NutraLife Biosciences Inc. (“NutraLife” or “NLBS”), (OTC Markets OTCQB: NLBS) today announced financial results for its fiscal 2019 first quarter ended March 31, 2019. The Company posted quarterly revenue of $720,799 and quarterly loss per diluted share of $0.01. These results compare to revenue of $722,905 and loss per diluted share of $0.01 for the same quarter of last year.  For the quarter ended March 31, 2019, the Company’s total assets were $4,462,098 compared to $1,830,329 for the same quarter in 2018, an increase of 144%.

For the Three Months Ended March 31, 2019

Q1 2019, Sales for Q1 2019 were $720,799 compared to $722,905 for the same period in 2018.

Q1 2019, Cash & Cash Equivalents at the End of the Period were $676,822 compared to $151,707 for the same period in 2018.

Q1 2019, Proceeds from the sale of stock was $2,224,480 compared to $0 for the same period in 2018.

Q1 2019, Receivables increased to  $115,484 at March 31, 2019 from $54,082 for the same period in 2018.

Q1 2019, Loss from Operations was $994,306 compared to $595,561 for the same period in 2018. 

Q1 2019, Cash used by operations was $1,208,126 compared to $6,900 for the same period in 2018.

Q1 2019, General & Administrative Expenses were $901,167 compared to $418,422 for the same period in 2018.

The Loss from Operations is the result of increases in expenses related to the Company’s positioning for growth.  The Company incurred significant expenses related to the purchase of supplies and inventory needed to support an increase in production capacity. In addition, the Company needed to increase its staffing resulting in higher payroll costs during the quarter.  These increases directly impacted the costs of sales for this quarter. Other expenses were incurred related to research and development and marketing costs that directly impacted the Company’s general and administrative expenses for the quarter.

The Company incurred costs from investing activities aggregating $859,507 that consist of the purchase of property and equipment totaling $729,507 and the acquisition of intellectual property of $130,000.  The property and equipment represent payments made towards the construction of a 9,000 square foot modular “clean room” and processing equipment for use at the Company’s new facility. The intellectual property is a patent for a dermal patch to prevent bites from insects, including mosquitoes.

“We are pleased to report our 1st quarter 2019 financial results and an increase in the Company’s total assets of more than 144% to $4,462,098 compared to $1,830,329 for the same period in 2018,” said Edgar Ward, NutraLife’s Chief Executive Officer. “The results reflect the Company’s investment in and expansion of its operations, manufacturing capacity and vertical integration into the life sciences industry.”

The statements herein are qualified in their entirety to the Company’s financial statements included in its Quarterly Report on Form 10-Q for the period ended March 31, 2019, filed with the Securities & Exchange Commission on May 15, 2019.

About NutraLife BioSciences

Edgar Ward founded NutraLife in 2010 and since that time he has served as its Chief Executive Officer, President and Director. Under Mr Ward’s direction, NutraLife’s revenues increased from $225,000 in 2016 to more than $3.7 million in 2018. NutraLife’s Coconut Creek manufacturing facility has been registered with the Food and Drug Administration, and its manufacturing facility has operated in accordance with the Good Manufacturing Processes Standard (GMP) for more than five years. NutraLife’s products are tested by its in-house laboratory chemists for strength, purity and contaminants such as heavy metals, pesticides, and solvents. NutraLife offers thirteen different core formulations which it modifies to meet the specifications of its private label customers. NutraLife provides approximately 50 different variations of its core formulations. NutraLife’s private label products include CBD infused oral sprays, tinctures, pet drops, pain balms, face creams, and nutraceutical oral spray products that support daily health and wellness uses.

Forward-Looking Statements

This press release contains statements of a forward-looking nature about NutraLife BioSciences, Inc. (“NutraLife” or the “Company”) ). These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect the Company’s financial condition, results of operations, business strategy and financial needs. There is no assurance that the Company’s current expectations and projections are accurate or that the Company’s plans to process hemp with GEG will be successful. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the Section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on April 2, 2019. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on the Company’s business or the extent to which any factor, or combination of factors may cause actual results to differ from those contained in any forward-looking statements. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applies.

Company Contact:

NutraLife BioSciences, Inc.

6601 Lyons Road, Suite L-6

Coconut Creek, FL  33073

Telephone 888-509-8901

www.NutraLifeBioSciences.com